BGI Genomics Can Develop DNA Tech During Patent Appeal

Law360 (August 12, 2020, 5:02 PM EDT) -- Chinese genetics company BGI Genomics can continue developing its DNA sequencing products as it appeals the scope of a preliminary injunction that gave Illumina total control of the U.S. market for the technology, a California federal judge has ruled.

U.S. District Judge William H. Orrick on Tuesday granted Shenzhen-based BGI's motion to pause parts of the injunction issued in June as the Federal Circuit considers whether the order improperly threatened to restrict other activities that didn't infringe Illumina's patents. Notably, BGI is not challenging the preliminary infringement findings.

"Although I found that Illumina had demonstrated a likelihood of success on the merits in my order,...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!